That's not a convincing argument. Listen to AMLN cc when CEO said FDA raised the QT issue before, but AMLN didn't know it was an approvability issue.
Please don't raise Bydureon to the larger issue of overall survival of healthcare system. Everyone tried to raise this issue when their drug isn't approved. Healthcare system is a lot more complex than this.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.